GLP-1s & Substance Use: Lower Risk Found | [Year] Update

The medications gaining attention for weight management – drugs like semaglutide and others in the GLP-1 receptor agonist class – may offer a surprising benefit beyond metabolic health: a potential reduction in the risk of developing substance use disorders. Emerging research suggests these therapies, initially designed to treat type 2 diabetes and obesity, could influence brain pathways involved in addiction, offering a novel approach to tackling a complex public health challenge. This potential impact is prompting a re-evaluation of how we understand and treat conditions ranging from alcohol dependence to compulsive behaviors.

Early Signals and the Role of GLP-1

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) mimic the effects of a naturally occurring hormone, GLP-1, which plays a role in regulating appetite and blood sugar. Yet, GLP-1 receptors aren’t limited to the digestive system; they’re also found in brain regions associated with reward and motivation. This broader influence is what’s drawing the attention of researchers investigating addiction. A paper published in the Journal of the Endocrine Society in October 2025 highlighted the encouraging potential of GLP-1RAs in treating both alcohol and other substance use disorders. The Endocrine Society reported on this research, noting that early studies in both animals and humans suggest these treatments may assist reduce substance use.

The current landscape of substance use disorder treatment is limited. According to the research, less than a quarter of people received treatment in 2023, despite the significant individual and societal consequences. Barriers to access, including stigma, contribute to this underutilization. The potential for GLP-1RAs to address the underlying neurobiological drivers of addiction could represent a significant step forward.

Beyond Weight Loss: Impact on Cravings and Brain Pathways

The initial excitement surrounding GLP-1 drugs stemmed from their effectiveness in promoting weight loss and curbing food cravings. However, clinicians began observing an unexpected side effect: a reduction in cravings for substances beyond food, including alcohol, drugs, and even behavioral addictions like gambling. Researchers at Brown University are actively investigating these broader effects. Carolina Haass-Koffler, associate professor of psychiatry and human behavior at Brown, explained that GLP-1s appear to work “more holistically, helping the brain and the body,” potentially representing a turning point in addiction psychiatry.

Professor Haass-Koffler’s lab has a long-standing interest in the role of hormones in addiction, having previously studied insulin, ghrelin, and leptin. Their current research focuses on how GLP-1s influence craving at the biological level. This is crucial given that craving is a central feature of addiction, driving the compulsive seeking and use of substances despite negative consequences.

What the Science Shows – and Doesn’t Show

While the initial findings are promising, it’s important to emphasize that research is still in its early stages. A 2022 review published in the British Journal of Pharmacology explored the role of GLP-1 in addictive disorders, highlighting the complex interplay between this hormone and brain circuits involved in reward and motivation. The review underscores that drug, alcohol, and tobacco use disorders represent a significant global burden, and current treatment options are often inadequate.

The clinical trials conducted to date have been relatively little, and more robust studies are needed to confirm these findings. It’s also crucial to understand the mechanisms by which GLP-1RAs exert their effects. Researchers are investigating whether these drugs directly impact dopamine signaling, reduce impulsivity, or alter other brain processes involved in addiction. Correlation does not equal causation, and it remains to be determined whether GLP-1RAs directly cause a reduction in substance use or if the effect is indirect.

Defining Substance Use Disorder and Current Treatment Gaps

Substance use disorders are diagnosed based on a set of criteria encompassing physical dependence, risky use, social problems, and impaired control. The consequences of these disorders are far-reaching, impacting individuals, families, and communities. Alcohol, in particular, is identified as the most harmful drug, contributing to accidents, violence, and a range of health problems. The limited access to effective treatment, coupled with the stigma surrounding addiction, exacerbates the problem.

What Comes Next: Clinical Trials and Further Research

The current wave of interest in GLP-1RAs for addiction treatment is driving a surge in clinical trials. Researchers are now designing larger, more rigorous studies to evaluate the efficacy and safety of these drugs in diverse populations. These trials will aim to determine optimal dosages, identify potential side effects, and assess the long-term impact of GLP-1RAs on substance use behaviors. Further research will also focus on identifying individuals who are most likely to benefit from this treatment approach. The National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) are actively involved in funding and conducting these studies.

Beyond clinical trials, researchers are also exploring the potential of GLP-1RAs as a preventative measure. Could these drugs be used to reduce the risk of developing substance use disorders in individuals who are vulnerable due to genetic predisposition or environmental factors? This is a longer-term goal, but one that holds significant promise for public health.